[go: up one dir, main page]

ZA201803719B - Stable solid dispersions of eliglustat hemitartrate - Google Patents

Stable solid dispersions of eliglustat hemitartrate

Info

Publication number
ZA201803719B
ZA201803719B ZA2018/03719A ZA201803719A ZA201803719B ZA 201803719 B ZA201803719 B ZA 201803719B ZA 2018/03719 A ZA2018/03719 A ZA 2018/03719A ZA 201803719 A ZA201803719 A ZA 201803719A ZA 201803719 B ZA201803719 B ZA 201803719B
Authority
ZA
South Africa
Prior art keywords
solid dispersions
stable solid
eliglustat hemitartrate
eliglustat
hemitartrate
Prior art date
Application number
ZA2018/03719A
Inventor
Ramanaiah Chennuru
Srinivas Laxminarayan Pathi
Venkata Srinivas Pullela
Dharmaraj Ramachandra Rao
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ZA201803719B publication Critical patent/ZA201803719B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
ZA2018/03719A 2017-06-05 2018-06-05 Stable solid dispersions of eliglustat hemitartrate ZA201803719B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721019661 2017-06-05

Publications (1)

Publication Number Publication Date
ZA201803719B true ZA201803719B (en) 2019-04-24

Family

ID=62791787

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/03719A ZA201803719B (en) 2017-06-05 2018-06-05 Stable solid dispersions of eliglustat hemitartrate

Country Status (2)

Country Link
WO (1) WO2018225085A1 (en)
ZA (1) ZA201803719B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395463T3 (en) 2001-07-16 2013-02-15 Genzyme Corporation An N-acylphingosine glucosyltransferase inhibitor
ME02477B (en) 2009-11-27 2017-02-20 Genzyme Corp Genz 112638 for the treatment of Gaucher or Fabry disease in combination therapy
CA2954030A1 (en) 2014-07-03 2016-01-07 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
ES2716420T3 (en) 2015-04-14 2019-06-12 Sandoz Ag Crystalline eliglustat hydrochloride

Also Published As

Publication number Publication date
WO2018225085A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
IL275365A (en) 6-azaindole compounds
IL272888B1 (en) Novel uses of piperidinyl-indole derivatives
IL250511A0 (en) Solid state forms of ibrutinib
EP3438474B8 (en) Piece of furniture
HU4602U (en) Set of saggar assembly
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
HUE056357T2 (en) Derivatives of sobetirome
SI3524234T1 (en) Solid state forms of sofosbuvir
IL274627A (en) Solid state form of valbenazine
IL265628A (en) Solid state forms of valbenazine
PT3661491T (en) Use of 3-methylmethcathinone
IL256159B (en) Solid dispersions of coenzyme q10
IL246979A0 (en) Solid state forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
EP3384921A4 (en) New use of thiopeptin
EP3468578A4 (en) Uses of il-41
IL263673A (en) Solid state forms of spiro-oxindole compounds
HU4603U (en) Set of saggar assembly
HUE050745T2 (en) Use of levelling compound
GB201602857D0 (en) Connection of rotatable parts
IL263363A (en) Polymorph of nintedanib
ZA201808437B (en) Determination of feedback timing
ZA201803719B (en) Stable solid dispersions of eliglustat hemitartrate
GB2553887B (en) Arrangement of line connections
IL254666A0 (en) Solid state form of eldecalcitol